CytomX Therapeutics (CTMX) Accumulated Depreciation & Amortization (2016 - 2024)
Historic Accumulated Depreciation & Amortization for CytomX Therapeutics (CTMX) over the last 11 years, with Q4 2024 value amounting to $16.2 million.
- CytomX Therapeutics' Accumulated Depreciation & Amortization rose 1050.52% to $16.2 million in Q4 2024 from the same period last year, while for Dec 2024 it was $16.2 million, marking a year-over-year increase of 1050.52%. This contributed to the annual value of $16.2 million for FY2024, which is 1050.52% up from last year.
- Latest data reveals that CytomX Therapeutics reported Accumulated Depreciation & Amortization of $16.2 million as of Q4 2024, which was up 1050.52% from $14.7 million recorded in Q4 2023.
- CytomX Therapeutics' 5-year Accumulated Depreciation & Amortization high stood at $16.2 million for Q4 2024, and its period low was $11.4 million during Q4 2020.
- Its 5-year average for Accumulated Depreciation & Amortization is $14.1 million, with a median of $14.4 million in 2022.
- Its Accumulated Depreciation & Amortization has fluctuated over the past 5 years, first surged by 2625.41% in 2020, then soared by 219.16% in 2023.
- Over the past 5 years, CytomX Therapeutics' Accumulated Depreciation & Amortization (Quarter) stood at $11.4 million in 2020, then grew by 21.06% to $13.8 million in 2021, then rose by 3.91% to $14.4 million in 2022, then grew by 2.19% to $14.7 million in 2023, then increased by 10.51% to $16.2 million in 2024.
- Its last three reported values are $16.2 million in Q4 2024, $14.7 million for Q4 2023, and $14.4 million during Q4 2022.